检索结果-南通市图书馆

世界核心医学期刊文摘（妇产科学分册） 2005年第1期1卷 50-51页

作者： penson r.t. Dignan F. Seiden M.V 王刚 Division of Hematology a nd Oncology Department of Medicine Massachusetts Gen. Hospital 02114 Boston MA United States

Background. recurrent ovarian cancer (OVCA) has become the model for ca ncer as a chronic disease, yet little is known about what motivates patients and physic ians in treatment choices. Methods. We investigated the attitudes of patients wi th epithelial OVCA and staff towards palliative chemotherapy for recurrent OVCA with a cross-sectional questionnaire study. results. Instruments were developed and piloted in 15 patients. this explor.t.ry study reflects substantial bias in the sample populations. One hundred twenty-two patients and 37 staff were enro lled in the US and 39 patients and 25 staff were enrolled in the UK. UK patients had a lower educational status (P = 0.001), lower stage disease (P = 0.025), an d less prior lines of chemotherapy (P tients had recurrent OV CA and 67%of staff were physicians. Seventy-three percent of patients recalled a discussion about prognosis and 74%wanted to know details of the prognosis fo r a typical patient (US = UK). Most patients (48%) thought that their physician was realistic, and 57%of staff felt that they were optimistic. the vastmajor.t.y of both staff and patients thought that patients positively reinterpr.t.d what they were told. Five percent of staff thought that palliative care was incomp atiblewhen considering chemotherapy as an option for.t.eir second recurrence o f OVCA, compared with 36%of US patients, significantly more than the 12%of UK patients (P = 0.007). Patients thought that standard chemotherapy for a second r ecurrence of OVCA produced remission in 50%and cure in 15%of patients. Staff r eported 20%and 0%, respectively. Fifty percent of patients and 57%of staff wo uldwant chemotherapy as an asymptomatic patient with a normal Ct and a rising CA -125. Patients generally appear.t. be very tolerant of grade II chemotherapy-i nduced toxicity with staff being less tolerant than patients of nausea, anorexia , diarrhea, and rash. Staff r.t.d life prolongation by 3 months to 1 year very m uch

关键词：复发性卵巢癌姑息性治疗姑息化疗标准化疗横断面调查慢性疾病生命延续无症状患者毒性反应探索性研究

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

接受大剂量依洛福芬治疗患者的视锥损害

引用

世界核心医学期刊文摘（眼科学分册） 2005年第6期1卷 18-18页

作者： Lee M.S. Gupta N. penson r.t. 韩静 Cole Eye Institute/i-32 Cleveland Clinic Foundation 9500 Euclid Ave Cleveland OH 44124 United States

Objectives: to describe the clinical, perimetric, and electror.t.nographic (ErG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient’ s r.t.nas. Design: Observational case series. Methods: the patients were examined clinically, including perimetric and ErG evaluations. Eyes from patient 1 and healthy postmortem eyes were processed for histopathologic and immunocytochemistry studies with antibodies specific for cones, rods, and reactiveMü ller cells. Main Outcome Measures: Clinical signs and symptoms, perimetry, ErG, r.t.nal histopathologic and immunocytochemistry study results. results: All 4 patients had ErG changes consistent with abnormal cone responses and relatively normal rod responses. Compared with control eyes, the r.t.na of patient 1 had approximately half the normal numbers of macular cones and fewer peripheral cones. the number of rods were normal but all rod and cone outer segments were shortened. Conclusion: High-dose irofulven treatment causes cone-specific damage with relative sparing of rods.

关键词：视锥视杆视网膜电图免疫细胞化学视网膜组织外节组织病理学功能不良病例研究观察性

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

奥拉帕利维持治疗BrCA 1/2突变铂敏感复发性卵巢癌患者(SOLO2/ENGOt-Ov21):一项双盲随机对照Ⅲ期试验的最终分析

引用

肿瘤药学 2021年第3期11卷 275-279页

作者： Andrés Poveda Anne Floquet Jonathan A Ledermann rebecca Asher richard t penson Amit M Oza Jacob Korach tomasz Huzarski Sandro Pignata Michael Friedlander Alessandra Baldoni tjoung-Won Park-Simon Kenji tamura Gabe S Sonke Alla Lisyanskaya Jae-Hoon Kim Elias Abdo Filho tsveta Milenkova Elizabeth S Lowe Phil rowe Ignace Vergote Eric Pujade-Lauraine the SOLO/ENGOt-Ovinvestigators 王娟(校) 李征(校) 不详

背景既往发表的SOLO2/ENGOt-Ov21试验的第一部分研究结果表明,作为BrCA1或BrCA2(BrCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者... 详细信息

背景既往发表的SOLO2/ENGOt-Ov21试验的第一部分研究结果表明,作为BrCA1或BrCA2(BrCA1/2)突变铂敏感型的高级别浆液性或子宫内膜样卵巢癌复发患者使用奥拉帕利可延长无进展生存期。因此,本研究的最终分析目的是研究奥拉帕利对这类患者总生存期的影响。方法本研究是一项在16个国家123个医疗中心进行的双盲、随机、安慰剂对照、Ⅲ期临床试验。纳入标准包括:年龄≥18岁;ECOG体能状态评分基线水平为0~1分;组织学检查确诊为复发性、高级别浆液性或高级别子宫内膜样卵巢癌,包括原发性腹膜癌或输卵管癌;以及既往接受过2种或2种以上铂类药物的治疗方案。入选患者按2∶1分配到奥拉帕利组(150 mg片剂,每日2次口服,共300 mg)或安慰剂组;根据既往化疗后是否缓解以及无铂治疗间隔时长进行分层;受试者、治疗提供者和数据分析人员在治疗分配时均设盲。主要终点是既往已报道过的无进展生存期;总生存期作为重要的次要终点之一,在所有随机分配的患者中进行分析;安全性评估在至少接受过1次给药的所有患者中进行。结果2013年9月3日—2014年11月21日,共295例患者参与了试验并被随机分到奥拉帕利组(196例,66%)或安慰剂组(99例,34%)治疗。奥拉帕利组患者中位随访时间为65.7个月(IQr:63.6~69.3),安慰剂组为64.5个月(IQr:63.4~68.7)。奥拉帕利组中位总生存期为51.7个月(95%CI:41.5~59.1),安慰剂组为38.8个月(95%CI:31.4~48.6)(Hr=0.74,95%CI:0.54~1.00,P=0.054)。安慰剂组38%接受PArP抑制剂治疗的患者未作调整。治疗引发的最常见的Ⅲ级以上不良事件为贫血,奥拉帕利组发生率为21%(41/195),安慰剂组为2%(2/99)。

关键词：安慰剂 Ⅲ期临床试验输卵管癌铂类药物患者参与组织学检查 BrCA SOLO

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：